Overview Dividends

(NTRA) Natera - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6323071042

Prenatal Screening, Carrier Screening, Cancer Monitoring, Transplant Assessment, Genetic Profiling

NTRA EPS (Earnings per Share)

EPS Growth (3Y CAGR): 216.81%
EPS Trend (3Y Correlation): 81.8%

NTRA Revenue

Revenue Growth (3Y CAGR): 41.45%
Revenue Trend (3Y Correlation): 99.2%

Description: NTRA Natera October 16, 2025

Natera (NTRA) is a global molecular diagnostics firm that leverages next-generation sequencing to offer a portfolio of non-invasive prenatal tests (Panorama, Vistara, Horizon), hereditary cancer and carrier-screening assays (Empower, Anora), and specialty oncology and transplant monitoring tools (Signatera, Altera, Prospera, Renasight). The company also provides the cloud-based analytics platform Constellation and distributes its products through a mix of direct sales, laboratory partners, and collaborations with BGI Genomics and Foundation Medicine.

In FY 2024 Natera reported $1.03 billion in revenue, reflecting a 28 % year-over-year increase driven primarily by strong growth in its prenatal and oncology segments. The firm’s gross margin expanded to 78 % as it scaled its high-margin NIPT assays, while its cash-flow conversion improved to $180 million, underscoring the capital-efficient nature of its SaaS-enabled test platform. Key sector drivers include rising global demand for non-invasive prenatal screening-projected to exceed $5 billion by 2028-and expanding reimbursement for liquid-biopsy oncology tests, which together create a tailwind for Natera’s recurring-revenue model.

If you’re looking to deepen your valuation analysis, a quick review of ValueRay’s quantitative models for NTRA can surface hidden upside and risk factors worth exploring further.

NTRA Stock Overview

Market Cap in USD	24,937m
Sub-Industry	Biotechnology
IPO / Inception	2015-07-02

NTRA Stock Ratings

Growth Rating	64.9%
Fundamental	47.6%
Dividend Rating	-
Return 12m vs S&P 500	33.4%
Analyst Rating	4.48 of 5

NTRA Dividends

Currently no dividends paid

NTRA Growth Ratios

Growth Correlation 3m	81%
Growth Correlation 12m	22.2%
Growth Correlation 5y	42.5%
CAGR 5y	60.67%
CAGR/Max DD 3y (Calmar Ratio)	1.52
CAGR/Mean DD 3y (Pain Ratio)	6.60
Sharpe Ratio 12m	0.54
Alpha	30.36
Beta	1.737
Volatility	40.42%
Current Volume	1108.9k
Average Volume 20d	1087.9k
Stop Loss	184.9 (-3.8%)
Signal	0.18

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (-253.2m TTM) > 0 and > 6% of Revenue (6% = 117.9m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 13.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 53.29% (prev 72.56%; Δ -19.27pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.11 (>3.0%) and CFO 186.7m > Net Income -253.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (136.4m) change vs 12m ago 11.02% (target <= -2.0% for YES)

Gross Margin 62.91% (prev 53.85%; Δ 9.06pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 120.0% (prev 89.68%; Δ 30.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -38.18 (EBITDA TTM -211.9m / Interest Expense TTM 6.47m) >= 6 (WARN >= 3)

Altman Z'' -7.80

(A) 0.60 = (Total Current Assets 1.43b - Total Current Liabilities 384.8m) / Total Assets 1.76b

(B) -1.56 = Retained Earnings (Balance) -2.74b / Total Assets 1.76b

warn (B) unusual magnitude: -1.56 — check mapping/units

(D) -5.36 = Book Value of Equity -2.74b / Total Liabilities 510.9m

Total Rating: -7.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 47.60

1. Piotroski 4.50pt = -0.50

2. FCF Yield 0.43% = 0.22

3. FCF Margin 5.32% = 1.33

4. Debt/Equity 0.16 = 2.49

5. Debt/Ebitda 3.79 = -2.47

6. ROIC - WACC (= -31.49)% = -12.50

7. RoE -22.21% = -2.50

8. Rev. Trend 99.21% = 7.44

9. EPS Trend 81.77% = 4.09

What is the price of NTRA shares?

As of October 28, 2025, the stock is trading at USD 192.22 with a total of 1,108,907 shares traded.
Over the past week, the price has changed by +1.92%, over one month by +17.86%, over three months by +39.29% and over the past year by +59.24%.

Is Natera a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Natera (NASDAQ:NTRA) is currently (October 2025) a stock to sell. It has a ValueRay Fundamental Rating of 47.60 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NTRA is around 205.27 USD . This means that NTRA is currently overvalued and has a potential downside of 6.79%.

Is NTRA a buy, sell or hold?

Natera has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NTRA.

Strong Buy: 12
Buy: 8
Hold: 0
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the NTRA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	194	0.9%
Analysts Target Price	194	0.9%
ValueRay Target Price	236.7	23.2%

NTRA Fundamental Data Overview October 20, 2025

Market Cap USD = 24.94b (24.94b USD * 1.0 USD.USD)
P/S = 12.6952
P/B = 17.6447
Beta = 1.737
Revenue TTM = 1.96b USD
EBIT TTM = -246.9m USD
EBITDA TTM = -211.9m USD
Long Term Debt = 115.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 93.4m USD (from shortTermDebt, last quarter)
Debt = 196.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -803.9m USD (from netDebt column, last quarter)
Enterprise Value = 24.12b USD (24.94b + Debt 196.1m - CCE 1.02b)
Interest Coverage Ratio = -38.18 (Ebit TTM -246.9m / Interest Expense TTM 6.47m)
FCF Yield = 0.43% (FCF TTM 104.6m / Enterprise Value 24.12b)
FCF Margin = 5.32% (FCF TTM 104.6m / Revenue TTM 1.96b)
Net Margin = -12.89% (Net Income TTM -253.2m / Revenue TTM 1.96b)
Gross Margin = 62.91% ((Revenue TTM 1.96b - Cost of Revenue TTM 728.6m) / Revenue TTM)
Gross Margin QoQ = 63.50% (prev 63.21%)
Tobins Q-Ratio = 13.73 (Enterprise Value 24.12b / Total Assets 1.76b)
Interest Expense / Debt = 0.52% (Interest Expense 1.03m / Debt 196.1m)
Taxrate = -0.27% (negative due to tax credits) (275.0k / -100.7m)
NOPAT = -247.6m (EBIT -246.9m * (1 - -0.27%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.72 (Total Current Assets 1.43b / Total Current Liabilities 384.8m)
Debt / Equity = 0.16 (Debt 196.1m / totalStockholderEquity, last quarter 1.25b)
Debt / EBITDA = 3.79 (negative EBITDA) (Net Debt -803.9m / EBITDA -211.9m)
Debt / FCF = -7.69 (Net Debt -803.9m / FCF TTM 104.6m)
Total Stockholder Equity = 1.14b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.41% (Net Income -253.2m / Total Assets 1.76b)
RoE = -22.21% (Net Income TTM -253.2m / Total Stockholder Equity 1.14b)
RoCE = -19.67% (EBIT -246.9m / Capital Employed (Equity 1.14b + L.T.Debt 115.8m))
RoIC = -19.17% (negative operating profit) (NOPAT -247.6m / Invested Capital 1.29b)
WACC = 12.33% (E(24.94b)/V(25.13b) * Re(12.42%) + D(196.1m)/V(25.13b) * Rd(0.52%) * (1-Tc(-0.00)))
Discount Rate = 12.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.92%
[DCF Debug] Terminal Value 53.56% ; FCFE base≈104.6m ; Y1≈68.6m ; Y5≈31.4m
Fair Price DCF = 2.60 (DCF Value 356.9m / Shares Outstanding 137.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 81.77 | EPS CAGR: 216.8% | SUE: 2.13 | # QB: 1
Revenue Correlation: 99.21 | Revenue CAGR: 41.45% | SUE: 2.75 | # QB: 10

Additional Sources for NTRA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle